These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 36427080)
1. Appropriate use of tapentadol: focus on the optimal tapering strategy. Vellucci R; Fornasari D Curr Med Res Opin; 2023 Jan; 39(1):123-129. PubMed ID: 36427080 [TBL] [Abstract][Full Text] [Related]
2. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647 [TBL] [Abstract][Full Text] [Related]
3. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Candiotti KA; Gitlin MC Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361 [TBL] [Abstract][Full Text] [Related]
5. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry. Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059 [TBL] [Abstract][Full Text] [Related]
6. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists]. Schwittay A; Schumann C; Litzenburger BC; Schwenke K MMW Fortschr Med; 2012 Oct; 154 Suppl 3():85-93. PubMed ID: 23133884 [TBL] [Abstract][Full Text] [Related]
7. Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials. Freynhagen R; Elling C; Radic T; Sohns M; Liedgens H; James D; McCool R; Edwards M Curr Med Res Opin; 2021 Jan; 37(1):89-100. PubMed ID: 33032466 [TBL] [Abstract][Full Text] [Related]
8. [Tapentadol versus classical WHO-III opioids for chronic back pain. Health services research study based on representative data from health insurance funds]. Kern KU; Vogelmann T; Tölle TR MMW Fortschr Med; 2022 Apr; 164(Suppl 6):19-27. PubMed ID: 35449488 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of tapentadol for the treatment of chronic low back pain in elderly patients. Freo U; Furnari M; Ambrosio F; Navalesi P Aging Clin Exp Res; 2021 Apr; 33(4):973-982. PubMed ID: 32418129 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Afilalo M; Morlion B Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531 [TBL] [Abstract][Full Text] [Related]
11. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406 [TBL] [Abstract][Full Text] [Related]
12. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437 [TBL] [Abstract][Full Text] [Related]
13. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients. Jung JY; Chon HJ; Choi YJ; Yeon SE; Choi SY; Lee KH Support Care Cancer; 2022 Jul; 30(7):6103-6112. PubMed ID: 35420330 [TBL] [Abstract][Full Text] [Related]
14. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice]. Agbalaka A; Schwenke K; Litzenburger B MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931 [TBL] [Abstract][Full Text] [Related]
15. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data. Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642 [TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047 [TBL] [Abstract][Full Text] [Related]
17. Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data. Schwittay A; Sohns M; Heckes B; Elling C Pain Res Manag; 2020; 2020():5759265. PubMed ID: 32351639 [TBL] [Abstract][Full Text] [Related]
18. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings. Alshehri FS Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332 [TBL] [Abstract][Full Text] [Related]
19. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States. Neil N; Merchant S; Provenzano D; Ogden K; Mody SH J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013 [TBL] [Abstract][Full Text] [Related]
20. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Coluzzi F; Ruggeri M Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]